

June 9, 2025

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that Dr. Sanjeev Kumar Panchal, Managing Director has offered to resign as the Managing Director of the Company, ipso facto, as a Director of the Company, with effect from close of business hours on June 30, 2025, as he would be taking up a Global role within the AstraZeneca Group based in Gaithersburg, Maryland, US.

While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company

Further, based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors in their meeting held today i.e., June 9, 2025, have appointed Mr. Praveen Rao Akkinipally as an Additional Director and the Managing Director of the Company, with effect from July 1, 2025.

As required under the Schedule III of the listing regulations, the resignation letter received from Dr. Sanjeev Panchal is attached herewith as Annexure - A

Further, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as Annexure – B.

Thanking you,

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Date: June 9, 2025

To
The Board of Directors
AstraZeneca Pharma India Limited
Bangalore
India

Dear Sirs/ Madam,


Sub: Resignation as Managing Director upon transition to a Global role within the AstraZeneca Group

Please note that following my appointment to a Global role within the AstraZeneca Group based in Gaithersburg, Maryland, US, I will be stepping down as Managing Director of the Company with effect from the end of business hours on June 30, 2025, and in terms of my appointment, ipso facto, as a Director of the Company. Consequently, I would also be resigning from my membership on the Committees of the Board wherein I am currently a member.

I sincerely thank all my colleagues on the Board for their support and guidance during my tenure as Managing Director of the Company. I also would like to place on record my appreciation for the support extend to me by the senior management team and all employees of the Company.

Thanking you,

Yours sincerely,


Sanjeev Kumar Panchal

Annexure - B

Sl. No	Particulars	Resignation of Dr. Sanjeev Panchal	Appointment of Mr. Praveen Rao Akkinepally
1	Reason for change Viz. appointment, resignation, removal, death or otherwise	Resignation of Dr. Sanjeev Panchal as the Managing Director, ipso facto as the Director of the Company.	Appointment of Mr. Praveen Rao Akkinepally (DIN: 11137771) as Additional Director and also as Managing Director of the Company.
2	Date of Appointment/ Cessation/Term of appointment	Close of business hours on June 30, 2025 (cessation).	July 1, 2025 (appointment) Term: For a period of three (3) years commencing from July 1, 2025
3	Brief Profile	Not Applicable	Mr. Praveen Rao Akkinepally is a seasoned commercial leader with over 20 years of experience spanning the US, global markets, and India in Oncology and Biopharmaceuticals. He has a proven track record of driving transformative business growth at AstraZeneca, including leading the launch of multiple brands and pioneering global commercialization strategies. Recognized with several AstraZeneca Excellence and CEO Awards, he is also committed to building high-performing, inclusive teams—championing gender diversity and employee engagement. As an Oncology Business Unit Head for India, he has overseen rapid growth, advanced AstraZeneca’s market position, and set new standards for oncology launches, while actively advocating for improved cancer care policy in India. Further, he has served on the Cancer Round Tables for the Federation of Indian Chambers of Commerce and Industry (FICCI) where he has championed key policy priorities to improve cancer care in the country.

			Mr. Praveen Rao Akkinepally holds an MBA from The University of Michigan, Ross School of Business and Master's in Public Health from Johns Hopkins University, Bloomberg School of Public Health.
4	Disclosure of Relationships between Directors	Not Applicable	Mr. Praveen Rao Akkinepally is not related to any of the Directors of the Company.
5	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Not Applicable	Mr. Praveen Rao Akkinepally is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.